Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
Income Statement
Follow revenue through to earnings.
Revenue
$4.05M
FY 2025 · Annual
+115.6% YoYOperating Income
-$30.58M
FY 2025 · Annual
Net Income
-$50.22M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.2M | 958K | 1.5M | 1.88M | 4.06M |
| Cost of Revenue | 778K | 976K | 1.09M | 1.14M | 3.87M |
| Gross Profit | 1.42M | (18K) | 413K | 740K | 190K |
| Gross Margin | 64.6% | -1.9% | 27.5% | 39.3% | 4.7% |
| Research & Development | 5.04M | 7.3M | 9.29M | 9.84M | 15.9M |
| Selling, General & Admin | 20.39M | 21.53M | 13.29M | 13.79M | 16.98M |
| Operating Expenses | 55.15M | 17.98M | 25.55M | 61.78M | 30.77M |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| EBITDA | (48.46M) | (13.31M) | (23.12M) | (59.02M) | (47.92M) |
| EBITDA Margin | -2204.6% | -1389.2% | -1538.5% | -3137.4% | -1181.7% |
| Operating Income | (53.73M) | (18M) | (25.14M) | (61.04M) | (30.58M) |
| Operating Margin | -2444.3% | -1878.6% | -1672.4% | -3245.1% | -754.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 209K | 83K | 52K | 84K | 109K |
| Other Income / Expenses | 854K | (615K) | 281K | 378K | (19.64M) |
| Income Before Tax | (52.87M) | (18.61M) | (24.86M) | (60.66M) | (50.22M) |
| Pre-Tax Margin | -2405.4% | -1942.8% | -1653.7% | -3225.0% | -1238.5% |
| Income Tax Expense | (9.26M) | 0 | 0 | 0 | 0 |
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Net Margin | -2916.2% | -7609.8% | -1848.4% | -3225.0% | -1238.5% |
| EPS (Basic) | (14.40) | (20.00) | (3.75) | (4.66) | (1.65) |
| EPS (Diluted) | (14.40) | (20.00) | (3.75) | (4.66) | (1.65) |
| 4.45M | 5.54M | 7.65M | 13.07M | 30.48M | |
| 4.45M | 5.54M | 7.65M | 13.07M | 30.48M |
IMDX Earnings Waterfall · TTM
NASDAQ:IMDX · Revenue to Net Income
Key Ratios
Analysis
$1.9M of revenue converted into -$47.8M of net income for the selected period. Gross margin is -431.9% and net margin is -5369.2%, showing how much revenue survives after costs and taxes. EPS is $-1.51, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Sep 21, 2026 | |
| 10-Q | Quarterly report | Aug 10, 2026 | |
| 8-K | Current report | Aug 10, 2026 | |
| S-8 | S-8 filing | Jul 24, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jul 6, 2026 |
How much revenue does IMDX generate?
Insight Molecular Diagnostics Inc. (IMDX) reported $4.05M of revenue in fiscal 2025.
Is IMDX profitable?
Insight Molecular Diagnostics Inc. (IMDX) reported -$50.22M of net income, with a net margin of -1238.5%.
Continue the stock analysis
Jump to another research area for this company.